Scholarlink

<p>We investigated the effect of the nucleoside uridine on the activities of key enzymes of oxidative phosphorylation (succinate dehydrogenase, SDH) and glycolysis (lactate dehydrogenase, LDH) in peripheral blood lymphocytes, and on oxidative metabolism in the blood serum of rats in the rotenone and 6-OHDA models of Parkinson’s disease. Both models were characterized by increased SDH and LDH activities in lymphocytes and accumulation of lipid peroxides in the blood serum. Injections of uridine, affecting the functioning of mitochondrial K-ATP channel (mitoKATP), to animals at a dose of 30 mg/kg body weight for 28 days mitigated SDH and LDH hyperactivation in lymphocytes and reduced the serum level of LPO products. Specific mitoKATP inhibitor 5-hydroxydecanoate (5 mg/kg) eliminated the effect of uridine. The role of mitoKATP in the protective effect of uridine in a model of Parkinson’s disease is discussed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Analysis of the Effect of Uridine on Oxidative and Energy Metabolism in the Blood during Administration of Rotenone and 6-Hydroxydopamine in Rats

  • 期刊论文

  • 发表日期：

    2026年1月1日

查看全文
  • N. V. Khunderyakova,
  • T. V. Polyakova,
  • V. P. Medvedeva,
  • I. V. Bulgin,
  • A. E. Malkov,
  • V. V. Mironov,
  • N. V. Khmil,
  • A. G. Medentsev,
  • G. D. Mironova

摘要

We investigated the effect of the nucleoside uridine on the activities of key enzymes of oxidative phosphorylation (succinate dehydrogenase, SDH) and glycolysis (lactate dehydrogenase, LDH) in peripheral blood lymphocytes, and on oxidative metabolism in the blood serum of rats in the rotenone and 6-OHDA models of Parkinson’s disease. Both models were characterized by increased SDH and LDH activities in lymphocytes and accumulation of lipid peroxides in the blood serum. Injections of uridine, affecting the functioning of mitochondrial K-ATP channel (mitoKATP), to animals at a dose of 30 mg/kg body weight for 28 days mitigated SDH and LDH hyperactivation in lymphocytes and reduced the serum level of LPO products. Specific mitoKATP inhibitor 5-hydroxydecanoate (5 mg/kg) eliminated the effect of uridine. The role of mitoKATP in the protective effect of uridine in a model of Parkinson’s disease is discussed.